Combination treatment with clomipramine and fluvoxamine: Drug monitoring, safety, and tolerability data

Journal of Clinical Psychiatry

Volumn 57, Issue 6, 1996, Pages 257-264

  Szegedi, Armin ^a   Wetzel, Hermann ^a   Leal, Marytza ^a   Härtter, Sebastian ^a   Hiemke, Christoph ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYNORCLOMIPRAMINE; ALPRAZOLAM; CLOMIPRAMINE; DIAZEPAM; DRUG METABOLITE; FLUVOXAMINE; LORAZEPAM; NORCLOMIPRAMINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INSOMNIA; LIVER TOXICITY; MALE; MYOCLONUS; OBSESSION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; SOMNOLENCE; TREMOR;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CLOMIPRAMINE; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG THERAPY, COMBINATION; ELECTROENCEPHALOGRAPHY; FEMALE; FLUVOXAMINE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN UPTAKE INHIBITORS;

EID: 0029947678     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Nelson JC, Mazure CM, Bowers MB, et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991;48:303-307
2. Nelson JC. Combined treatment strategies in psychiatry. J Clin Psychiatry 1993;54(9, suppl):42-49
3. Weilburg JB, Rosenbaum JF, Biederman J, et al. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry 1989;50:447-449
4. Boyer WF, McFadden GA, Feighner JP. Clinical use of selective serotonin re-uptake inhibitors. In: Feighner JP, Boyer WF, eds. Selective Serotonin Re-Uptake Inhibitors: The Clinical Use of Citalopram, Fluoxetine, Fluvoxamine, Paroxetine, and Sertraline. New York, NY: John Wiley & Sons; 1991:153-160
5. Popli AP, Baldessarini RJ, Cole JO. Interactions of serotonin reuptake inhibitors with tricyclic antidepressants. Arch Gen Psychiatry 1994;51: 666-667
6. Vandel S, Bertschy G, Bonin B, et al. Tricyclic antidepressant plasma levels after fluoxetine addition. Neuropsychobiology 1992;25:202-207
7. Ciraulo DA, Shader RI. Fluoxetine drug-drug interactions, I: antidepressants and antipsychotics. J Clin Psychopharmacol 1990;10:48-50
8. Preskorn SH, Beber JH, Faul JC, et al. Serious adverse effects of combining fluoxetine and tricyclic antidepressants [letter]. Am J Psychiatry 1990;147:532
9. Aranow RB, Hudson JI, Pope HG Jr, et al. Elevated antidepressant plasma levels after addition of fluoxetine. Am J Psychiatry 1989;146:911-913
10. Bell IR, Cole JO. Fluoxetine induces elevation of desipramine level and exacerbation of geriatric nonpsychotic depression. J Clin Psychopharmacol 1988;8:447-448
11. Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-265
12. Brøsen K, Skjelbo E, Rasmussen BB, et al. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45:1211-1214
13. Härtter S, Hiemke C. Column switching and high-performance liquid chromatography in the analysis of amitriptyline, nortriptyline and hydroxylated metabolites in human plasma or serum. J Chromatogr A 1992; 578:273-282
14. Härtter S, Wetzel H, Hiemke C. Automated determination of fluvoxamine in plasma by column-switching high-performance liquid chromatography. Clin Chem 1992;38(10):2082-2086
15. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU Side Effect Rating Scale. Acta Psychiatr Scand 1987;76(suppl 334):1-100
16. Härtter S, Wetzel H, Hammes E, et al. Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. Psychopharmacology (Berl) 1993;110:302-308
17. Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J Clin Psychiatry 1991:52(6, suppl):23-33. Correction 1991;52:353
18. Della Corte L, Broadhurst AD, Sgaragli P, et al. Clinical response and tricyclic plasma levels during treatment with clomipramine. Br J Psychiatry 1979;134:390-400
19. Träskman L, Asberg M, Bertilsson L, et al. Plasma levels of chlorimipramine and its demethyl metabolite during treatment of depression. Clin Pharmacol Ther 1979;26(5):600-610
20. Linnoila M, Insel T, Kilts C, et al. Plasma steady-state concentrations of hydroxylated metabolites of clomipramine. Clin Pharmacol Ther 1982; 32(2):208-211
21. Bertschy G, Vandel S, Francois T, et al. Metabolic interaction between tricyclic antidepressant and fluvoxamine and fluoxetine: a pharmacogenetic approach. Clin Neuropharmacol 1992;15(suppl):78A-79A
22. Spina E, Campo GM, Avenoso A, et al. Interaction between fluvoxamine and imipramine/desipramine in four patients. Ther Drug Monit 1992;14: 194-196
23. Preskorn SH, Alderman J, Chung M, et al. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994;14:90-98
24. Alderman J, Greenblatt DJ, Allison J, et al. Desipramine pharmacokinetics with the serotonin reuptake inhibitors, paroxetine or sertraline. Neuropsychopharmacology 1994;10(3, suppl 2):263S
25. Preskorn SH. Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J Clin Psychiatry 1993;54(9, suppl):14-34
26. Rosenstein DL, Nelson JC, Jacobs SC. Seizures associated with antidepressants: a review. J Clin Psychiatry 1993;54:289-299
27. Lejoyeux M, Ades J, Rouillon F. Serotonin syndrome: incidence, symptoms and treatment CNS Drugs 1994;2(2):132-143
28. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148: 705-713
29. Garvey MJ, Tollefson GD. Occurrence of myoclonus in patients treated with cyclic antidepressants. Arch Gen Psychiatry 1987;44:269-272
30. Myers BA, Klerman GL, Hartmann E. Nocturnal cataclysms with myoclonus: a new side effect of clomipramine. Am J Psychiatry 1986;143: 1490-1491
31. Grohmann R, Schmidt LG, Antretter K, et al. Unerwünschte Wirkungen von Psychopharmaka-Ausgewählte Ergebnisse aus dem multizentrischen Zehnjahresporjekt AMÜP. Internist (Berl) 1990;31:468-474
32. Young RC, Alexopolous GS, Shamoian CA, et al. Plasma 10-hydroxynortriptyline and ECG changes in elderly depressed patients. Am J Psychiatry 1986;142:866-868
33. Schneider LS, Cooper TB, Severson JA, et al. Electrocardiographic changes with nortriptyline and 10-hydroxynortriptyline in elderly depressed outpatients. J Clin Psychopharmacol 1988;8:402-408
34. Pollock BG, Perel JM. Imipramine and 2-hydroxyimipramine: comparative cardiotoxicity and pharmacokinetics in swine. Psychopharmacology (Berl) 1992;109:57-62
35. Kutcher R, Reid K, Dubbin JD, et al. Electrocardiogram changes and therapeutic desipramine and 2-hydroxy-desipramine concentrations in elderly depressives. Br J Psychiatry 1986;148:676-679
36. Keck PE Jr, McElroy SL. Ratio of plasma fluoxetine to norfluoxetine concentrations and associated sedation. J Clin Psychiatry 1992;53: 127-129
37. McTavish D, Benfield P. Clomipramine: an overview of its pharmacological properties and a review of its therapeutic use in obsessive-compulsive disorder and panic disorder. Drugs 1990;39(1):136-153
38. Wilde MI, Plosker GL, Benfield P. Fluvoxamine: an updated review of its pharmacology, and therapeutic use in depressive illness. Drugs 1993;46 (5):895-924
39. Balant-Gorgia AE, Gex-Fabry M, Balant LP. Clinical pharmacokinetics of clomipramine. Clin Pharmacokinet 1991;20:447-462
40. Noguchi T, Shimoda K, Takahashi S. Clinical significance of plasma levels of clomipramine, its hydroxylated and desmethylated metabolites: prediction of clinical outcome in mood disorders using discriminant analysis of therapeutic drug monitoring data. J Affect Disord 1993;29:267-279
41. Benkert O, Wetzel H, Szegedi A. Serotonin dysfunction syndromes: a functional common denominator for classification of depression, anxiety, and obsessive-compulsive disorder. Int Clin Psychopharmacol 1993;8 (suppl 1):3-14
42. Mavissakalian MR, Jones B, Olson S, et al. Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels. J Clin Psychopharmacol 1990;10:261-268
43. Koran LM, Faravelli C, Pallanti S. Intravenous clomipramine for obsessive-compulsive disorder. J Clin Psychopharmacol 1994;14(3):216-217
44. Norman TR, Leonard BE. Fast-acting antidepressants: can the need be met? CNS Drugs 1994;2(2):120-131